MedTrace Logo

Presynaptic Imaging in Major Depressive Episodes After COVID-19

NCT06086366 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 90

Last updated 2026-02-11

No results posted yet for this study

Summary

The goal of this observational study focuses on understanding and addressing a subset of persistent neuropsychiatric symptoms occurring within 3 months after mild to moderate COVID-19 infection (COVID-DNP). COVID-DNP encompasses major depressive episodes (MDE) with or without additional neuropsychiatric symptoms.

Conditions

Interventions

OTHER

[11C]DTBZ PET scan

One \[11C\]DTBZ scan for vesicular monoamine transporter 2 (VMAT2)

OTHER

[18F]SDM8 PET scan

One \[18F\]SDM8 scan for synaptic vesicle glycoprotein 2A (SV2A)

OTHER

MRI scan

One MRI scan

Sponsors & Collaborators

  • Centre for Addiction and Mental Health

    lead OTHER

Principal Investigators

  • Jeffrey Meyer, M.D., PhD · Centre for Addiction and Mental Health

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-08-22
Primary Completion
2028-09-10
Completion
2028-09-10

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06086366 on ClinicalTrials.gov